1
|
Wang C, Liu Y, Wang Y, Li H, Zhang RX, He MS, Chen L, Wu NN, Liao Y, Deng ZL. Adenovirus-mediated siRNA targeting CXCR2 attenuates titanium particle-induced osteolysis by suppressing osteoclast formation. Med Sci Monit 2016; 22:727-35. [PMID: 26939934 PMCID: PMC4780823 DOI: 10.12659/msm.897243] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
Background Wear particle-induced peri-implant loosening is the most common complication affecting long-term outcomes in patients who undergo total joint arthroplasty. Wear particles and by-products from joint replacements may cause chronic local inflammation and foreign body reactions, which can in turn lead to osteolysis. Thus, inhibiting the formation and activity of osteoclasts may improve the functionality and long-term success of total joint arthroplasty. The aim of this study was to interfere with CXC chemokine receptor type 2 (CXCR2) to explore its role in wear particle-induced osteolysis. Material/Methods Morphological and biochemical assays were used to assess osteoclastogenesis in vivo and in vitro. CXCR2 was upregulated in osteoclast formation. Results Local injection with adenovirus-mediated siRNA targeting CXCR2 inhibited titanium-induced osteolysis in a mouse calvarial model in vivo. Furthermore, siCXCR2 suppressed osteoclast formation both directly by acting on osteoclasts themselves and indirectly by altering RANKL and OPG expression in osteoblasts in vitro. Conclusions CXCR2 plays a critical role in particle-induced osteolysis, and siCXCR2 may be a novel treatment for aseptic loosening.
Collapse
Affiliation(s)
- Chen Wang
- Department of Orthopedic Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland)
| | - Yang Liu
- Department of Orthopedic Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland)
| | - Yang Wang
- Department of Orthopedic Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland)
| | - Hao Li
- Department of Orthopedic Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland)
| | - Ran-Xi Zhang
- Department of Orthopedic Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland)
| | - Mi-Si He
- Department of Gynecologic Oncology, Chongqing Cancer Institute, Chongqing, China (mainland)
| | - Liang Chen
- Department of Orthopedic Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland)
| | - Ning-Ning Wu
- Department of Clinical Laboratory Testing Diagnostics, Chongqing Medical University, Chongqing, China (mainland)
| | - Yong Liao
- Institute for Viral Hepatitis, Key Laboratory of Molecular Biology for Infectious Diseases, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland)
| | - Zhong-Liang Deng
- Department of Orthopedic Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (mainland)
| |
Collapse
|
2
|
Abstract
Chemokine receptors are involved in various pathologies such as inflammatory diseases, cancer, and HIV infection. Small molecule and antibody-based antagonists have been developed to inhibit chemokine-induced receptor activity. Currently two small molecule inhibitors targeting CXCR4 and CCR5 are on the market for stem cell mobilization and the treatment of HIV infection, respectively. Antibody fragments (e.g., nanobodies) targeting chemokine receptors are primarily orthosteric ligands, competing for the chemokine binding site. This is opposed by most small molecules, which act as allosteric modulators and bind to the receptor at a topographically distinct site as compared to chemokines. Allosteric modulators can be distinguished from orthosteric ligands by unique features, such as a saturable effect and probe dependency. For successful drug development, it is essential to determine pharmacological parameters (i.e., affinity, potency, and efficacy) and the mode of action of potential drugs during early stages of research in order to predict the biological effect of chemokine receptor targeting drugs in the clinic. This chapter explains how the pharmacological profile of chemokine receptor targeting ligands can be determined and quantified using binding and functional experiments.
Collapse
|
3
|
Abstract
Chemokines and their receptors are known to play important roles in disease. More than 40 chemokine ligands and 20 chemokine receptors have been identified, but, to date, only two small molecule chemokine receptor antagonists have been approved by the FDA. The chemokine receptor CXCR3 was identified in 1996, and nearly 20 years later, new areas of CXCR3 disease biology continue to emerge. Several classes of small molecule CXCR3 antagonists have been developed, and two have shown efficacy in preclinical models of inflammatory disease. However, only one CXCR3 antagonist has been evaluated in clinical trials, and there remain many opportunities to further investigate known classes of CXCR3 antagonists and to identify new chemotypes. This Perspective reviews the known CXCR3 antagonists and considers future opportunities for the development of small molecules for clinical evaluation.
Collapse
Affiliation(s)
- Stephen P Andrews
- Heptares Therapeutics , BioPark, Broadwater Road, Welwyn Garden City, AL7 3AX, United Kingdom
| | - Rhona J Cox
- Respiratory, Inflammation & Autoimmunity iMed, AstraZeneca, Respiratory, Inflammation & Autoimmunity IMED , Pepparedsleden, 431 83 Mölndal, Sweden
| |
Collapse
|
4
|
Mladic M, Scholten DJ, Niessen WMA, Somsen GW, Smit MJ, Kool J. At-line coupling of LC-MS to bioaffinity and selectivity assessment for metabolic profiling of ligands towards chemokine receptors CXCR1 and CXCR2. J Chromatogr B Analyt Technol Biomed Life Sci 2015; 1002:42-53. [PMID: 26301479 DOI: 10.1016/j.jchromb.2015.08.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Revised: 08/03/2015] [Accepted: 08/04/2015] [Indexed: 11/28/2022]
Abstract
This study describes an analytical method for bioaffinity and selectivity assessment of CXCR2 antagonists and their metabolites. The method is based on liquid chromatographic separation (LC) of metabolic mixtures followed by parallel mass spectrometry (MS) identification and bioaffinity determination. The bioaffinity is assessed using radioligand binding assays in 96-well plates after at-line nanofractionation. The described method was optimized for chemokines and low-molecular weight CXCR2 ligands. The limits of detection (LODs; injected amounts) for MK-7123, a high affinity binder to both CXCR1 and CXCR2 receptors belonging to the diaminocyclobutendione chemical class, were 40pmol in CXCR1 binding and 8pmol in CXCR2 binding. For CXCL8, the LOD was 5pmol in both binding assays. A control compound was always taken along with each bioassay plate as triplicate dose-response curve. For MK-7123, the calculated IC50 values were 314±59nM (CXCR1 binding) and 38±11nM (CXCR2 binding). For CXCL8, the IC50 values were 6.9±1.4nM (CXCR1 binding) and 2.7±1.3nM (CXCR2 binding). After optimization, the method was applied to the analysis of metabolic mixtures of eight LMW CXCR2 antagonists generated by incubation with pig liver microsomes. Moreover, metabolic profiling of the MK-7123 compound was described using the developed method. Three bioactive metabolites were found, two of which were (partially) identified. This method is suitable for bioaffinity and selectivity assessment of mixtures targeting the CXCR2. In contrary to conventional LC-MS based metabolic profiling studies done at the early lead discovery stage, additional qualitative bioactivity information of drug metabolites is obtained with the method described.
Collapse
Affiliation(s)
- Marija Mladic
- Amsterdam Institute for Molecules Medicines and Systems, Division of BioAnalytical Chemistry, VU University Amsterdam, De Boelelaan 1083, 1081HV Amsterdam, The Netherlands; Amsterdam Institute for Molecules Medicines and Systems, Division of Medicinal Chemistry, VU University Amsterdam, De Boelelaan 1083, 1081HV Amsterdam, The Netherlands
| | - Danny J Scholten
- Amsterdam Institute for Molecules Medicines and Systems, Division of Medicinal Chemistry, VU University Amsterdam, De Boelelaan 1083, 1081HV Amsterdam, The Netherlands
| | - Wilfried M A Niessen
- Amsterdam Institute for Molecules Medicines and Systems, Division of BioAnalytical Chemistry, VU University Amsterdam, De Boelelaan 1083, 1081HV Amsterdam, The Netherlands; hyphen MassSpec, de Wetstraat 8, 2332XT Leiden, The Netherlands
| | - Govert W Somsen
- Amsterdam Institute for Molecules Medicines and Systems, Division of BioAnalytical Chemistry, VU University Amsterdam, De Boelelaan 1083, 1081HV Amsterdam, The Netherlands
| | - Martine J Smit
- Amsterdam Institute for Molecules Medicines and Systems, Division of Medicinal Chemistry, VU University Amsterdam, De Boelelaan 1083, 1081HV Amsterdam, The Netherlands
| | - Jeroen Kool
- Amsterdam Institute for Molecules Medicines and Systems, Division of BioAnalytical Chemistry, VU University Amsterdam, De Boelelaan 1083, 1081HV Amsterdam, The Netherlands.
| |
Collapse
|
5
|
Liu G, Chen Y, Qi F, Jia L, Lu XA, He T, Fu Y, Li L, Luo Y. Specific chemotherapeutic agents induce metastatic behaviour through stromal- and tumour-derived cytokine and angiogenic factor signalling. J Pathol 2015; 237:190-202. [PMID: 25988668 DOI: 10.1002/path.4564] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Revised: 04/08/2015] [Accepted: 05/07/2015] [Indexed: 11/09/2022]
Abstract
Recent studies reveal that chemotherapy can enhance metastasis due to host responses, such as augmented expression of adhesion molecules in endothelial cells and increased populations of myeloid cells. However, it is still unclear how tumour cells contribute to this process. Here, we observed that paclitaxel and carboplatin accelerated lung metastasis in tumour-bearing mice, while doxorubicin and fluorouracil did not. Mechanistically, paclitaxel and carboplatin induced similar changes in cytokine and angiogenic factors. Increased levels of CXCR2, CXCR4, S1P/S1PR1, PlGF and PDGF-BB were identified in the serum or primary tumour tissues of tumour-bearing mice treated by paclitaxel. The serum levels of CXCL1 and PDGF-BB and the tissue level of CXCR4 were also elevated by carboplatin. On the other hand, doxorubicin and fluorouracil did not induce such changes. The chemotherapy-induced cytokine and angiogenic factor changes were also confirmed in gene expression datasets from human patients following chemotherapy treatment. These chemotherapy-enhanced cytokines and angiogenic factors further induced angiogenesis, destabilized vascular integrity, recruited BMDCs to metastatic organs and mediated the proliferation, migration and epithelial-to-mesenchymal transition of tumour cells. Interestingly, inhibitors of these factors counteracted chemotherapy-enhanced metastasis in both tumour-bearing mice and normal mice injected intravenously with B16F10-GFP cells. In particular, blockade of the SDF-1α-CXCR4 or S1P-S1PR1 axes not only compromised chemotherapy-induced metastasis but also prolonged the median survival time by 33.9% and 40.3%, respectively. The current study delineates the mechanism of chemotherapy-induced metastasis and provides novel therapeutic strategies to counterbalance pro-metastatic effects of chemo-drugs via combination treatment with anti-cytokine/anti-angiogenic therapy.
Collapse
Affiliation(s)
- Guanghua Liu
- The National Engineering Laboratory for Anti-Tumour Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Cancer Biology Laboratory, School of Life Sciences, Tsinghua University, Beijing, People's Republic of China
| | - Yang Chen
- The National Engineering Laboratory for Anti-Tumour Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Cancer Biology Laboratory, School of Life Sciences, Tsinghua University, Beijing, People's Republic of China
| | - Feifei Qi
- The National Engineering Laboratory for Anti-Tumour Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Cancer Biology Laboratory, School of Life Sciences, Tsinghua University, Beijing, People's Republic of China
| | - Lin Jia
- The National Engineering Laboratory for Anti-Tumour Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Cancer Biology Laboratory, School of Life Sciences, Tsinghua University, Beijing, People's Republic of China
| | - Xin-an Lu
- The National Engineering Laboratory for Anti-Tumour Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Cancer Biology Laboratory, School of Life Sciences, Tsinghua University, Beijing, People's Republic of China
| | - Ting He
- The National Engineering Laboratory for Anti-Tumour Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Cancer Biology Laboratory, School of Life Sciences, Tsinghua University, Beijing, People's Republic of China
| | - Yan Fu
- The National Engineering Laboratory for Anti-Tumour Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Cancer Biology Laboratory, School of Life Sciences, Tsinghua University, Beijing, People's Republic of China
| | - Lin Li
- The National Engineering Laboratory for Anti-Tumour Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Cancer Biology Laboratory, School of Life Sciences, Tsinghua University, Beijing, People's Republic of China
| | - Yongzhang Luo
- The National Engineering Laboratory for Anti-Tumour Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, People's Republic of China.,Cancer Biology Laboratory, School of Life Sciences, Tsinghua University, Beijing, People's Republic of China
| |
Collapse
|
6
|
Abstract
INTRODUCTION Small-molecule antagonists of CXC chemokine receptor 2 (CXCR2) have attracted a considerable amount of attention due to the key central role that this receptor plays in inflammatory conditions. Recently, several CXCR2 receptor antagonists have demonstrated promising proof of activity in early pulmonary clinical trials, which has stimulated additional efforts to identify new CXCR2 receptor antagonists. AREAS COVERED During the period 2009 - 2013, there were numerous patent publications from various companies claiming the discovery of novel CXCR2 receptor antagonists. Herein, an interpretation of these new patent publications combined with emerging disclosures from the peer-reviewed literature during this time frame is given. This review highlights the preferred or representative compounds from the patent applications along with relevant biological characterization. EXPERT OPINION Many of the new CXCR2 receptor antagonists described in this review represent closely related analogs to previously disclosed clinical candidates. With the recent discontinuation of several CXCR2 receptor antagonists in the clinic, additional clinical trial information for CXCR2 receptor antagonists, both past and present, will determine the long-term therapeutic potential of these compounds for the treatment of a variety of inflammatory disorders.
Collapse
Affiliation(s)
- Michael P Dwyer
- Department of Medicinal Chemistry, Merck Research Laboratories , 126 E. Lincoln Ave, RY800-D101, Rahway, NJ 07065-0900 , USA +1 732 594 1733 ; +1 732 594 9490 ;
| | | |
Collapse
|
7
|
Vischer HF, Siderius M, Leurs R, Smit MJ. Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases? Nat Rev Drug Discov 2014; 13:123-39. [DOI: 10.1038/nrd4189] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
8
|
Nichols SE, Hernández CX, Wang Y, McCammon JA. Structure-based network analysis of an evolved G protein-coupled receptor homodimer interface. Protein Sci 2013; 22:745-54. [PMID: 23553730 PMCID: PMC3690714 DOI: 10.1002/pro.2258] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2012] [Revised: 02/27/2013] [Accepted: 03/17/2013] [Indexed: 01/24/2023]
Abstract
Crystallographic structures and experimental assays of human CXC chemokine receptor type 4 (CXCR4) provide strong evidence for the capacity to homodimerize, potentially as a means of allosteric regulation. Even so, how this homodimer forms and its biological significance has yet to be fully characterized. By applying principles from network analysis, sequence-based approaches such as statistical coupling analysis to determine coevolutionary residues, can be used in conjunction with molecular dynamics simulations to identify residues relevant to dimerization. Here, the predominant coevolution sector lies along the observed dimer interface, suggesting functional relevance. Furthermore, coevolution scoring provides a basis for determining significant nodes, termed hubs, in the network formed by residues found along the interface of the homodimer. These node residues coincide with hotspots indicating potential druggability. Drug design efforts targeting such key residues could potentially result in modulation of binding and therapeutic benefits for disease states, such as lung cancers, lymphomas and latent HIV-1 infection. Furthermore, this method may be applied to any protein-protein interaction.
Collapse
Affiliation(s)
- Sara E Nichols
- Howard Hughes Medical Institute, University of California, San Diego, La Jolla, California 92093-0365, USA.
| | | | | | | |
Collapse
|
9
|
Carter PH. Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 - 2012. Expert Opin Ther Pat 2013; 23:549-68. [PMID: 23428142 DOI: 10.1517/13543776.2013.771168] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
INTRODUCTION CC chemokine receptor 2 (CCR2) is a key mediator of the activation and migration of inflammatory monocytes. As such, it has been investigated extensively as a target for therapeutic intervention in a diverse range of diseases. AREAS COVERED This article reviews both the patent and peer-reviewed literature on the discovery of CCR2 antagonists from January 2009 to December 2012. Developments have occurred within each of the major chemical families of CCR2 antagonists, and are framed in that context. As has been true historically, a number of the compound families also exhibit substantial activity against the related CC chemokine receptor 5 (CCR5), making them formally CCR2/5-dual antagonists. EXPERT OPINION Significant progress continues to be made in identifying novel, potent CCR2 antagonists. In addition, researchers have had success in addressing issues related to selectivity, cardiac safety, and preclinical pharmacokinetics. Establishing proof-of-concept in clinical trials remains the primary challenge for the field.
Collapse
Affiliation(s)
- Percy H Carter
- Research & Development, Bristol-Myers Squibb Co., Princeton, NJ 08543, USA.
| |
Collapse
|